Pandemic Timeline

Treatments

NIH upgrades recommendation on ivermectin, making it an acceptable option for use in COVID-19

Tags:

This new designation upgraded the status of ivermectin from “against” to “neither for nor against”, which is the same recommendation given to monoclonal antibodies and convalescent plasma, both widely used across the nation.

— Front Line COVID-19 Critical Care Alliance (FLCCC), January 15, 2021

So that paragraph on the NIH page now reads:

There is insufficient evidence for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of ivermectin for the treatment of COVID-19.

— “Ivermectin,” NIH

The recommendation was revised based on data presented by the Front Line Covid-19 Critical Care Alliance (FLCCC).  At least now, the NIH does not recommend against ivermectin.  Your physician should now be able to prescribe ivermectin for COVID-19 based on the FDA off-label policy without risk of losing their hospital privileges or license.  Just hand them the NIH report, perhaps with the press release and the FDA off-label policy.

For the fact checkers out there:  “No evidence” is not the same as “insufficient evidence.”  There is evidence.  If there was no evidence, the NIH would not have felt compelled to upgrade their recommendation on ivermectin based on what FLCCC members presented, considering that the politically preferred jabs were about to be granted Emergency Use Authorizations.  There was no way the NIH would have come out “for” ivermectin or say that there was “sufficient evidence” for its use.  That could have derailed the EUAs, and so would have been politically taboo at the time.

Sources:

Related:

See also, on this site:

Comments are closed.